Stock Events

Stock Events

Tango Therapeutics 

$30.52
27
-$0.12-0.39% 19:59 Today
+$0.37+1.21%21:14After hours

Statistics

Day High
31.28
Day Low
29.87
52W High
34.39
52W Low
5.75
Volume
2,739,843
Avg. Volume
4,248,827
Mkt Cap
4.97B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.37
-0.2
-0.03
0.14
Expected EPS
-0.319375
Actual EPS
N/A

Financials

-162.85%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
62.38MRevenue
-101.59MNet Income

Analyst Ratings

39.44Average Price Target
The highest estimate is 69.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
78%
Hold
22%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TNGX. It's not an investment recommendation.
NVIDIA
10
NVDA
Apple
7
AAPL
Microsoft
7
MSFT
AMD
7
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is involved in gene editing, a technology that could compete with Tango Therapeutics' approach to targeting cancer.
Intellia Therapeutics
NTLA
Mkt Cap2.45B
Intellia Therapeutics is a leading developer of CRISPR gene editing, directly competing in the genetic medicine space.
Editas Medicine
EDIT
Mkt Cap560.14M
Editas Medicine operates in the CRISPR gene editing sector, offering technologies that could rival Tango's cancer therapies.
Beam Therapeutics
BEAM
Mkt Cap3.58B
Beam Therapeutics focuses on base editing, a form of gene editing that could offer alternative treatments to those developed by Tango.
Sangamo Therapeutics
SGMO
Mkt Cap30.66M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same therapeutic areas as Tango.
Allogene Therapeutics
ALLO
Mkt Cap717.92M
Allogene Therapeutics is focused on allogeneic CAR T-cell therapies, which could be in direct competition with Tango's cancer treatment approaches.
Fate Therapeutics
FATE
Mkt Cap340.35M
Fate Therapeutics is working on programmed cellular immunotherapies, which could compete with Tango's cancer treatment strategies.
Novartis
NVS
Mkt Cap305.1B
Novartis is a large pharmaceutical company with a broad portfolio, including advanced therapies that could compete with Tango's cancer treatments.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences, with its acquisition of Kite Pharma, has a strong presence in cell therapy for cancer, competing with Tango Therapeutics.

About

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Show more...
CEO
Dr. Barbara L. Weber M.D.
Employees
155
Country
United States
ISIN
US87583X1090

Listings

XNAS
US
TNGX
BOATS
BOATS
TNGX.BOATS

0 Comments

Share your thoughts

FAQ

What is Tango Therapeutics stock price today?▼
The current price of TNGX is $30.52 USD — it has decreased by -0.39% in the past 24 hours. Watch Tango Therapeutics stock price performance more closely on the chart.
What is Tango Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Tango Therapeutics stocks are traded under the ticker TNGX.
Is Tango Therapeutics stock price growing?▼
TNGX stock has risen by +3.6% compared to the previous week, the month change is a -3.3% fall, over the last year Tango Therapeutics has showed a +405.3% increase.
What is Tango Therapeutics market cap?▼
Today Tango Therapeutics has the market capitalization of 4.97B
When is the next Tango Therapeutics earnings date?▼
Tango Therapeutics is going to release the next earnings report on August 12, 2026.
What were Tango Therapeutics earnings last quarter?▼
TNGX earnings for the last quarter are -0.32 USD per share, whereas the estimation was -0.31 USD resulting in a -2.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tango Therapeutics revenue for the last year?▼
Tango Therapeutics revenue for the last year amounts to 62.38M USD.
What is Tango Therapeutics net income for the last year?▼
TNGX net income for the last year is -101.59M USD.
How many employees does Tango Therapeutics have?▼
As of July 09, 2026, the company has 155 employees.
In which sector is Tango Therapeutics located?▼
Tango Therapeutics operates in the Health & Wellness sector.
When did Tango Therapeutics complete a stock split?▼
Tango Therapeutics has not had any recent stock splits.
Where is Tango Therapeutics headquartered?▼
Tango Therapeutics is headquartered in Boston, United States.